Article
Lack of resistant mutation development after receiving short-course zidovudine plus lamivudine to prevent mother-to-child transmission.
AIDS (London, England) - 22 Jul 2005
Chokephaibulkit Kulkanya, Chaisilwattana Pongsakdi, Vanprapar Nirun, Phongsamart Wanatpreeya, Sutthent Ruengpung
Abstract excerpt
A short-course regimen of zidovudine plus lamivudine starting from 34 weeks' gestation in pregnant women to prevent mother-to-child HIV infection, and discontinued after delivery, was evaluated for the development of resistance at 6 weeks postpartum. No resistant mutation was found in 32 women. One of the three infected infants carried the M184V and K219Q mutations.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.